STAT Plus: U.S. biotechs fear the coronavirus outbreak will delay their China-based research
Biotech investors and executives are growing worried that restrictions intended to contain the coronavirus epidemic in China could delay the work Chinese contract research organizations perform for American startups — particularly if those restrictions last for several months.
The impact on biotechs so far appears to be minor, in part because the restrictions — including travel bans and workplace closures — coincided with the Lunar New Year, when many businesses expect employees to be away from work anyway.
Continue to STAT Plus to read the full story…
